{"Title":"OptiNose","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"35","Founded":"","Address":"","Phone":"(267) 364-3500","Web_address":"http://www.optinose.com","Market_cup":"$566.2mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-42.8 mil (last 12 months)","Symbol":"OPTN","Exchange":"NASDAQ","Shares":"7.5","Price_range":"$16.00 - $16.00","Est_volume":"$120.0 mil","Manager":"Jefferies/ Piper Jaffray/ BMO Capital Markets/ RBC Capital Markets","CO_managers":"-","Exp_to_trade":"10/13/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. Our lead product, XHANCE, is a therapeutic utilizing our proprietary Breath Powered exhalation delivery system, or EDS, that delivers a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps."}